论文部分内容阅读
目的:观察阿法骨化醇联合ARB类药物减少尿蛋白的临床疗效。方法:选取我院自2014年1月至2014年12月间慢性肾炎、糖尿病肾病、高血压肾病的患者60例,随机分为二组,对照组30例采用ARB治疗8周,实验组30例在此基础上加用阿法骨化醇治疗,于治疗前后观察尿蛋白减少情况及肾功能、血电解质的变化。结果:2组有效率实验组为86.7%,对照组为73.3%,差异有显著性(P<0.05)。结论:阿法骨化醇联合ARB类药物对减少慢性肾炎、糖尿病肾病、高血压肾病有良好减少尿蛋白治疗作用。
Objective: To observe the clinical efficacy of alfacalciferol and ARB in reducing urinary protein. Methods: Sixty patients with chronic nephritis, diabetic nephropathy and hypertensive nephropathy from January 2014 to December 2014 in our hospital were randomly divided into two groups. In the control group, 30 cases were treated with ARB for 8 weeks, and 30 cases in the experimental group On this basis, alfacalcidol was added, and the changes of urinary protein, renal function and blood electrolytes were observed before and after treatment. Results: The effective rate in the two groups was 86.7% in the experimental group and 73.3% in the control group, with significant difference (P <0.05). Conclusion: Alfacalciferol combined with ARB drugs can effectively reduce urinary protein in reducing chronic nephritis, diabetic nephropathy and hypertensive nephropathy.